The role of computational methods for automating and improving clinical target volume definition.

Automatic image segmentation Clinical target volume Computational tumor growth models

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
12 2020
Historique:
received: 10 07 2020
revised: 01 10 2020
accepted: 01 10 2020
pubmed: 12 10 2020
medline: 15 4 2021
entrez: 11 10 2020
Statut: ppublish

Résumé

Treatment planning in radiotherapy distinguishes three target volume concepts: the gross tumor volume (GTV), the clinical target volume (CTV), and the planning target volume (PTV). Over time, GTV definition and PTV margins have improved through the development of novel imaging techniques and better image guidance, respectively. CTV definition is sometimes considered the weakest element in the planning process. CTV definition is particularly complex since the extension of microscopic disease cannot be seen using currently available in-vivo imaging techniques. Instead, CTV definition has to incorporate knowledge of the patterns of tumor progression. While CTV delineation has largely been considered the domain of radiation oncologists, this paper, arising from a 2019 ESTRO Physics research workshop, discusses the contributions that medical physics and computer science can make by developing computational methods to support CTV definition. First, we overview the role of image segmentation algorithms, which may in part automate CTV delineation through segmentation of lymph node stations or normal tissues representing anatomical boundaries of microscopic tumor progression. The recent success of deep convolutional neural networks has also enabled learning entire CTV delineations from examples. Second, we discuss the use of mathematical models of tumor progression for CTV definition, using as example the application of glioma growth models to facilitate GTV-to-CTV expansion for glioblastoma that is consistent with neuroanatomy. We further consider statistical machine learning models to quantify lymphatic metastatic progression of tumors, which may eventually improve elective CTV definition. Lastly, we discuss approaches to incorporate uncertainty in CTV definition into treatment plan optimization as well as general limitations of the CTV concept in the case of infiltrating tumors without natural boundaries.

Identifiants

pubmed: 33039428
pii: S0167-8140(20)30838-0
doi: 10.1016/j.radonc.2020.10.002
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-25

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Jan Unkelbach (J)

Department of Radiation Oncology, University Hospital Zurich, Switzerland. Electronic address: jan.unkelbach@usz.ch.

Thomas Bortfeld (T)

Division of Radiation Biophysics, Massachusetts General Hospital and Harvard Medical School, Boston, USA.

Carlos E Cardenas (CE)

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA.

Vincent Gregoire (V)

Radiation Oncology Dept. Centre Léon Bérard, Lyon, France.

Wille Hager (W)

Department of Physics, Medical Radiation Physics, Stockholm University and Department of Oncology and Pathology, Medical Radiation Physics, Karolinska Institutet, Stockholm, Sweden.

Ben Heijmen (B)

Department of Radiation Oncology, Erasmus University Medical Center (Erasmus MC), Rotterdam, The Netherlands.

Robert Jeraj (R)

Department of Medical Physics, University of Wisconsin, Madison, USA.

Stine S Korreman (SS)

Department of Oncology and Danish Center for Particle Therapy, Aarhus University Hospital, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Roman Ludwig (R)

Department of Radiation Oncology, University Hospital Zurich, Switzerland.

Bertrand Pouymayou (B)

Department of Radiation Oncology, University Hospital Zurich, Switzerland.

Nadya Shusharina (N)

Division of Radiation Biophysics, Massachusetts General Hospital and Harvard Medical School, Boston, USA.

Jonas Söderberg (J)

RaySearch Laboratories, Stockholm, Sweden.

Iuliana Toma-Dasu (I)

Department of Physics, Medical Radiation Physics, Stockholm University and Department of Oncology and Pathology, Medical Radiation Physics, Karolinska Institutet, Stockholm, Sweden.

Esther G C Troost (EGC)

Dept. of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Dresden, Germany; Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiooncology - OncoRay, Dresden, Germany.

Eliana Vasquez Osorio (E)

Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH